Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? the Example of Vorapaxar

Victor L. Serebruany, Seth D. Fortmann, Moo Hyun Kim

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: In contrast to the vast majority of pharmaceuticals on the market, antiplatelet agents are widely prescribed in a uniform, 'one size fits all' manner, without conventional dose adjustments. However, strong evidence yielded from clinical trials repeatedly suggests that patients with a low body weight (LBW), the elderly and those with renal or hepatic impairment may benefit from reduced doses, while younger, heavier patients, males and diabetics may benefit from a dose escalation. Vorapaxar, a thrombin protease-activated receptor-1 inhibitor, has been tested in the TRA2P and TRACER clinical trials, but its efficacy and safety in patients with a LBW is unclear. Objective: To determine the impact of LBW on primary end point rates (PER) and bleeding risk after vorapaxar, as yielded from the TRA2P and TRACER secondary FDA review. Results: The LBW (

Original languageEnglish (US)
Pages (from-to)69-72
Number of pages4
Issue number2
StatePublished - Jan 1 2016


  • Bleeding
  • Body weight
  • Dose adjustment
  • Vorapaxar

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? the Example of Vorapaxar'. Together they form a unique fingerprint.

Cite this